Clinical spectrum of premature pubarche: Links to metabolic syndrome and ovarian hyperandrogenism

被引:81
作者
Ibanez, Lourdes [1 ,4 ]
Diaz, Ruben [1 ]
Lopez-Bermejo, Abel [2 ]
Victoria Marcos, Maria [3 ,4 ]
机构
[1] Univ Barcelona, Endocrinol Unit, Hosp St Joan de Deu, Barcelona 08950, Spain
[2] Dr Josep Trueta Hosp Univ Girona, Dept Pediat, Girona 17007, Spain
[3] Hosp Terrassa, Endocrinol Unit, Terrassa 08227, Spain
[4] CIBER Diabet & Enfermedades Metab Asociadas, Barcelona, Spain
关键词
Premature pubarche; Low birth weight; Ovarian hyperandrogenism; Metformin; Insulin; Visceral fat; LOW-BIRTH-WEIGHT; FOR-GESTATIONAL-AGE; GENE VARIABLE NUMBER; CORTICOTROPIN-RELEASING HORMONE; CAG REPEAT POLYMORPHISM; REVISED; 2003; CONSENSUS; IGF-BINDING PROTEIN-1; REDUCED FETAL-GROWTH; PRECOCIOUS PUBARCHE; ANDROGEN EXCESS;
D O I
10.1007/s11154-008-9096-y
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Premature pubarche-defined as the appearance of pubic hair before age 8 years in girls and 9 years in boys-has been traditionally considered a benign entity. However, recent evidence supports the notion that premature pubarche in girls may be a forerunner of the metabolic syndrome, and may precede the development of clinical ovarian androgen excess in adolescence. This sequence seems to occur more frequently when premature pubarche was preceded by reduced fetal growth and followed by excessive postnatal catch-up in height and particularly in weight; hyperinsulinemia appears to be a key factor in the development of this sequence of events. In girls with premature pubarche and a history of a low birth weight, puberty tends to start earlier and to have a faster course, so that final height may be moderately reduced. In these girls, metformin therapy may reverse the progression to clinical ovarian hyperandrogenism, normalize body composition and excess visceral fat, and delay pubertal progression without attenuating linear growth and bone mineralization, suggesting that adult height may be improved. Long-term follow-up of these patients is needed to fully determine the ultimate effects of insulin sensitization as well as the maintenance of these benefits after discontinuation of therapy.
引用
收藏
页码:63 / 76
页数:14
相关论文
共 129 条
[1]
Rasminogen activator inhibitor-1, adipose tissue and insulin resistance [J].
Alessi, Marie-Christine ;
Poggi, Marjorie ;
Juhan-Vague, Irene .
CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (03) :240-245
[2]
Diagnosis of polycystic ovarian syndrome: The Rotterdam criteria are premature [J].
Azziz, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (03) :781-785
[3]
Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline [J].
Azziz, Ricardo ;
Carmina, Enrico ;
Dewailly, Didier ;
Diamanti-Kandarakis, Evanthia ;
Escobar-Morreale, Hector F. ;
Futterweit, Walter ;
Janssen, Onno E. ;
Legro, Richard S. ;
Norman, Robert J. ;
Taylor, Ann E. ;
Witchel, Selma F. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) :4237-4245
[4]
TYPE 2 (NON-INSULIN-DEPENDENT) DIABETES-MELLITUS, HYPERTENSION AND HYPERLIPEMIA (SYNDROME-X) - RELATION TO REDUCED FETAL GROWTH [J].
BARKER, DJP ;
HALES, CN ;
FALL, CHD ;
OSMOND, C ;
PHIPPS, K ;
CLARK, PMS .
DIABETOLOGIA, 1993, 36 (01) :62-67
[5]
OVARIES IN SEXUAL PRECOCITY [J].
BRIDGES, NA ;
COOKE, A ;
HEALY, MJR ;
HINDMARSH, PC ;
BROOK, CGD .
CLINICAL ENDOCRINOLOGY, 1995, 42 (02) :135-140
[6]
The New Adipose Tissue and Adipocytokines [J].
Bulcao, Caroline ;
Ferreira, Sandra Roberta G. ;
Giuffrida, Fernando M. A. ;
Ribeiro-Filho, Fernando Flexa .
CURRENT DIABETES REVIEWS, 2006, 2 (01) :19-28
[7]
Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women [J].
Calvo, RM ;
Tellería, D ;
Sancho, J ;
San Millán, JL ;
Escobar-Morreale, HF .
FERTILITY AND STERILITY, 2002, 77 (04) :666-668
[8]
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [J].
Chang, J ;
Azziz, R ;
Legro, R ;
Dewailly, D ;
Franks, S ;
Tarlatzis, BC ;
Fauser, B ;
Balen, A ;
Bouchard, P ;
Dahlgren, E ;
Devoto, L ;
Diamanti, E ;
Dunaif, A ;
Filicori, M ;
Homburg, R ;
Ibanez, L ;
Laven, J ;
Magoffin, D ;
Nestler, J ;
Norman, RJ ;
Pasquali, R ;
Pugeat, M ;
Strauss, J ;
Tan, S ;
Taylor, A ;
Wild, R ;
Wild, S ;
Ehrmann, D ;
Lobo, R .
FERTILITY AND STERILITY, 2004, 81 (01) :19-25
[9]
Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? [J].
Cheang, Kai I. ;
Sharma, Susmeeta T. ;
Nestler, John E. .
GYNECOLOGICAL ENDOCRINOLOGY, 2006, 22 (11) :595-604
[10]
Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: Evidence for varied effects in hyperandrogenemic adolescent girls [J].
Chhabra, S ;
McCartney, CR ;
Yoo, RY ;
Eagleson, CA ;
Chang, RJ ;
Marshall, JC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (05) :2810-2815